Table 2 Participants’ baseline characteristics

Age (years)

11.67 ± 37.77

39.48 ± 11.03

0.52 ^a

Sex (female/male)

18/18

20/17

0.72^c

Height (cm)

166.73 ± 8.38

165.37 ± 8.82

0.50 ^a

Weight (kg)

72.33 ± 13.59

69.72 ± 14.54

0.43 ^a

BMI (kg/m²)

26.01 ± 4.41

25.61 ± 5.05

0.73 ^a

TAC (nmol/mL)

281.43 ± 53.35

259.92 ± 61.45

0.11^a

MDA (nmol/mL)

60.74 ± 16.06

63.30 ± 26.36

0.61 ^a

SOD (U/mL)

10.65 ± 4.08

10.21 ± 5.49

0.69 ^a

ESR (mm/h)

20.61 ± 19.68

17.56 ± 13.64

0.44 ^a

Pentraxin 3 (ng/mL)

13.49 ± 7.38

12.13 ± 8.33

0.37 ^a

SCCAI score

8.16 ± 2.48

9.02 ± 2.58

0.15 ^a

SIBDQ score

41.61 ± 10.95

42.08 ± 9.71

0.33 ^a

Disease duration (year)

7.16 ± 5.59

5.21 ± 5.02

0.12 ^a

Dose of Mesalazine (mg/day)

2277.77 ± 1614.41

1959.45 ± 1180.73

0.47^b

Family history n (%)

8 (22.22)

7 (18.91)

0.72^c

Current medication use n (%)

Mesalazine (oral)

30 (83.33)

32 (86.48)

0.23^c

Mesalazine (rectal)

11 (30.55)

12 (32.43)

0.32^c

Sulfasalazine

6 (16.66)

3 (8.10)

0.69^c

Prednisolone

3 (8.33)

3 (8.10)

0.35^c

Azathioprine

6 (16.66)

5 (13.51)

0.62^c